Envoy Medical — Third Quarter 2026 Earnings Summary

Envoy Medical reported a net loss of $5.24 million for the third quarter of 2026, driven by $3.077 million in research and development expenses and $2.125 million in general and administrative costs. The company achieved a significant clinical milestone by surpassing the six-month follow-up visit mark for all 56 patients in its pivotal trial of the investigational Acclaim fully implanted cochlear implant. Additionally, Envoy Medical submitted the second module of its Modular Premarket Approval application to the FDA and dismissed prior litigation with Atlas Merchant Capital without payment. As of September 30, 2026, the company held approximately $14.57 million in cash.